This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.
Under these circumstances, it is however not entirely clear how the future competitive landscape will look like, merger effects cannot be modelled with a high...
In a new article published in WuW – Wirtschaft und Wettbewerb (Competition Law & Economics), Johannes Dittrich, Sebastian Panthöfer and Lars Wiethaus delve...
Philip Marsden is a discussant during the session titled “Platform Economics, Digital Competition, and Regulation.” For more information on this event, click...
Max Planck Institute for Innovation and Competition as well as Charles River Associates invite you to a conference which will provide the full picture on the...
